Anacor Pharmaceuticals, Inc.
) recently announced positive results from a phase II
dose-ranging study conducted in adolescents for its atopic
dermatitis candidate, AN2728.
The randomized, double-blind, bilateral phase II study enrolled
86 adolescents with mild-to-moderate atopic dermatitis. For 28
days, the subjects were randomized 1:1 on either a once daily
(QD) or twice daily (BID) regimen.
A 71% improvement from baseline on the Atopic Dermatitis Severity
Index (ADSI) score was achieved by lesions treated under the
AN2728 2.0% BID regimen, while 66% of lesions achieved total or
partial clearance. Overall, the study showed that AN2728 is safe
and well tolerated.
Anacor Pharma expects to start a phase III program with the 2.0%
BID dosing regimen by the end of 2013.
A few weeks back, the company had announced positive results from
two phase III studies on its topical antifungal candidate,
tavaborole (AN2690). The studies, 301 and 302, evaluated the
candidate for the prevention of onychomycosis. They were
conducted under the US Food and Drug Administration's (FDA)
Special Protocol Assessment (SPA) program. Anacor Pharma intends
to seek US approval for the candidate in the indication in
We are encouraged by the pipeline progress at Anacor. We expect
investor focus to remain on the regulatory filing for AN2690 as
well as the initiation of late-stage studies on AN2728.
Anacor Pharma carries a Zacks Rank #3 (Hold). Currently,
Lannett Company, Inc.
WuXi Pharma Tech (Cayman) Inc.
) look more attractive in the pharma space with a Zacks Rank #1
ANACOR PHARMACT (ANAC): Free Stock Analysis
LANNETT INC (LCI): Free Stock Analysis Report
QLT INC (QLTI): Free Stock Analysis Report
WUXI PHARMATECH (WX): Free Stock Analysis
To read this article on Zacks.com click here.